Single cell Whole genome sequencing in peripheral

The National Heart Lung and Blood Institute (NHLBI), a division of the National Institutes of Health under the Department of Health and Human Services, is soliciting proposals for single cell whole genome sequencing services in peripheral blood samples from patients with VEXAS syndrome. This biotechnology research and development procurement seeks qualified contractors capable of performing advanced genomic analysis on individual cells to support clinical research objectives. The solicitation was posted on January 28, 2026, with proposals due by February 5, 2026, providing a one-week response window for interested parties. While the notice does not explicitly detail evaluation criteria, interested vendors should anticipate standard federal procurement evaluation factors including technical capability, cost-effectiveness, relevant experience, and project timeline feasibility. Potential applicants are advised to monitor the solicitation closely during this compressed timeline to ensure timely submission of all required documentation and clarifications.

No set-aside designations have been applied to this procurement, meaning all eligible vendors regardless of size or ownership classification may compete. The solicitation notice does not identify any incumbent contractors or provide specific award values or budget ranges, requiring interested parties to contact the agency or review the full solicitation document for financial parameters. Similarly, the quantity of samples to be sequenced, specific deliverables, and the overall project timeline are not specified in this summary notice. The place of performance and any facility requirements have not been disclosed in the available information. Contractors should anticipate that the National Heart Lung and Blood Institute will be the primary point of contact and likely performance location, though this should be confirmed upon receipt of the complete solicitation package.